Results 21 to 30 of about 19,808 (220)
Comparison of [11C]TZ1964B and [18F]MNI659 for PET imaging brain PDE10A in nonhuman primates [PDF]
, 2016 Phosphodiesterase 10A (PDE10A) inhibitors show therapeutic effects for diseases with striatal pathology. PET radiotracers have been developed to quantify in vivo PDE10A levels and target engagement for therapeutic interventions. The aim of this study was
Alagille, David +10 more
core +2 more sources
Translational Oncology, 2022 The validation of prostate specific membrane antigen (PSMA) as a molecular target in metastatic castration-resistant prostate cancer has stimulated the development of multiple classes of theranostic ligands that specifically target PSMA.
Thomas M. Jeitner +2 more
doaj +1 more source
Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors [PDF]
Journal of Nuclear Medicine, 2017 544 Objectives: Our understanding of the N-methyl-D-aspartate (NMDA) receptor subunit composition, localization as well as function has dramatically improved in recent years and has led to the identification of the GluN2B-subunit as a key contributor to excitotoxicity-induced apoptosis.
Elif, Hindié +2 more
openaire +2 more sources
Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. [PDF]
, 2013 There is increasing evidence that opioid analgesics may interfere with tumour growth. It is currently thought that these effects are mediated by transactivation of receptor tyrosine kinase (RTK)-controlled ERK1/2 and Akt signalling.
Ammer, Hermann +2 more
core +2 more sources
Modeling and Predicting Tumor Response in Radioligand Therapy [PDF]
Journal of Nuclear Medicine, 2018 The aim of this work was to develop a theranostic method that allows prediction of prostate-specific membrane antigen (PSMA)-positive tumor volume after radioligand therapy (RLT) based on a pretherapeutic PET/CT measurement and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling at the example of RLT using 177Lu-labeled PSMA for ...
Peter, Kletting +10 more
openaire +2 more sources
Advances in targeted Alpha therapy for prostate cancer [PDF]
, 2019 BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G +11 more
core +2 more sources
Fluoxetine: a case history of its discovery and preclinical development [PDF]
, 2014 Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N +20 more
core +2 more sources
Commercial and business aspects of alpha radioligand therapeutics
Frontiers in Medicine, 2023 Radioligand therapy (RLT) is gaining traction as a safe and effective targeted approach for the treatment of many cancer types, reflected by a substantial and growing commercial market (valued at $7.78 billion in 2021, with a projected value of $13.07 ...
Emanuele Ostuni, Martin R. G. Taylor
doaj +1 more source
Characterisation of nicotine receptors on human peripheral blood mononuclear cells (PBMC) [PDF]
, 2009 “The original publication is available at www.springerlink.com”. Copyright Springer. DOI: 10.1007/s00011-008-8171-xAim and objective: The aim of the work was to characterise the nAChRs on human PBMC.
Parsons, M. +2 more
core +1 more source
TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria [PDF]
, 2016 The 18-kDa translocator protein (TSPO) localizes in the outer mitochondrial membrane (OMM) of cells and is readily up-regulated under various pathological conditions such as cancer, inflammation, mechanical lesions and neurological diseases. Able to bind
Aghazadeh +189 more
core +1 more source